Breaking Finance News

Vical Incorporated (NASDAQ:VICL) stock price target increased to $3.50, issued a research note today by Zacks Investment Research

Yesterday Vical Incorporated (NASDAQ:VICL) traded 1.88% higher at $3.06. The company’s 50-day moving average is $3.90 and its 200-day moving average is $4.07. The last closing price is down -20.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 18,874 shares of the stock traded hands, down from an average trading volume of 35,988

In a report released on 9/21/2016 Zacks Investment Research increased the stock price target of Vical Incorporated (NASDAQ:VICL) to $3.50 indicating a possible upside of 0.14%.

Previously on 7/19/2016, H.C. Wainwright reported on Vical Incorporated (NASDAQ:VICL) increased the target price from $0.00 to $12.00. At the time, this indicated a possible upside of 1.75%.

See Chart Below

Vical Incorporated (NASDAQ:VICL)

Vical Incorporated has a 52 week low of $2.80 and a 52 week high of $5.40 The company’s market cap is currently $0.

General Information About Vical Incorporated (NASDAQ:VICL)

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *